Invivo Partners leads €20 million Series A round in Neumirna Therapeutics with Angelini Ventures

by Invivo Capital

Neumirna was founded with the mission to revolutionize the treatment paradigms for challenging neurological conditions, and is at the forefront of RNA therapeutics, harnessing the power of microRNAs (...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

SICC Innvierte, a vehicle managed by CDT...

by CDTI Innovación

With a target size of €250 million, the fund aims to complete betwee...

Photos Stream